As shown in Fig. 3d, e, the addition of PD-L1 blockade in PLK1122DC_TriVax led to dramatically reduced tumour progression and significantly increased median survival of the mice by more than 1-week as compared to those with PLK1122DC_TriVax alone, but complete tumour regressions were not obtained. This evidence concerns the gene CD274 and neoplasm.